Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Account Payables
Amounts the company owes suppliers for goods and services received.
Entera Bio Ltd.NASDAQ: ENTX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 104.5% from a year ago
Account payables stood at $274K at the end of Q1 FY2026, up 104.5% from a year earlier and down 38.8% from the prior quarter. Over 3 fiscal years it compounded at +197.6% a year.
Context
- Account payables amounted to 2.1% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +104.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 448K USD
- Year-over-year change
- +239.4%
- 4-year CAGR
- +28.2%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 448K | +239.4% |
| FY2024 | 2024-12-31 | 132K | +59.0% |
| FY2023 | 2023-12-31 | 83K | +388.2% |
| FY2022 | 2022-12-31 | 17K | -89.8% |
| FY2021 | 2021-12-31 | 166K | — |
Account Payables vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 account payables of $274K is the 8th highest of the 10 companies compared; the peer median is $2.34M.
- Its year-over-year change of +104.5% is the highest of 10, against a peer median of +7.8%.
- Account payables amounts to 2.1% of total assets for ENTX, versus a peer median of 2.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $71.08M | +10.7% | +26.6% | 38.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $4.42M | +82.0% | +45.5% | 6.6% |
| Mar 2026 | $3.95M | +28.2% | +25.3% | 13.3% | |
| Mar 2026 | $2.5M | -43.9% | +38.7% | 0.9% | |
| Mar 2026 | $2.34M | +7.8% | -54.1% | 2.0% | |
| Mar 2026 | $1.99M | -64.0% | -50.1% | 4.0% | |
| Mar 2026 | $1.66M | +56.7% | -30.4% | 1.2% | |
| Mar 2026 | $274K | +104.5% | +197.6% | 2.1% | |
| Apr 2026 | $252K | -11.3% | -14.6% | 1.7% | |
| Mar 2026 | $217K | -87.7% | +3.9% | 0.4% | |
| Peer median (excluding ENTX) | $2.34M | +7.8% | +3.9% | 2.0% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.